<code id='2144955C5F'></code><style id='2144955C5F'></style>
    • <acronym id='2144955C5F'></acronym>
      <center id='2144955C5F'><center id='2144955C5F'><tfoot id='2144955C5F'></tfoot></center><abbr id='2144955C5F'><dir id='2144955C5F'><tfoot id='2144955C5F'></tfoot><noframes id='2144955C5F'>

    • <optgroup id='2144955C5F'><strike id='2144955C5F'><sup id='2144955C5F'></sup></strike><code id='2144955C5F'></code></optgroup>
        1. <b id='2144955C5F'><label id='2144955C5F'><select id='2144955C5F'><dt id='2144955C5F'><span id='2144955C5F'></span></dt></select></label></b><u id='2144955C5F'></u>
          <i id='2144955C5F'><strike id='2144955C5F'><tt id='2144955C5F'><pre id='2144955C5F'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:hotspot    Page View:5775
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          In his State of the Union, Biden takes clear aim at 'Big Pharma'
          In his State of the Union, Biden takes clear aim at 'Big Pharma'

          PresidentBidendeliverstheStateoftheUnionaddresstoajointsessionofCongressattheU.S.CapitolonThursday.A

          read more
          Malaria cases in Florida and Texas: Here’s what you need to know
          Malaria cases in Florida and Texas: Here’s what you need to know

          MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

          read more

          Infant mortality in U.S. rose last year for first time in decades: CDC

          APPhoto/EricGayTheU.S.infantmortalityraterose3%lastyear—thelargestincreaseintwodecades,accordingtoth